Anti-B blood group antibodies (Anti-B)

Anti-B blood group antibodies are naturally occurring isoagglutinins found in the plasma of individuals with blood group A or O (StatPearls, 2023). These antibodies are primarily of the IgM class, though IgG forms are common in group O individuals, and they specifically target the B-antigen carbohydrate structures on red blood cells and vascular endothelium (NCBI, 2022). In clinical practice, Anti-B antibodies are a major barrier to ABO-incompatible blood transfusions and organ transplantations, as their binding triggers complement-mediated hemolysis or hyperacute graft rejection (American Journal of Transplantation, 2019). Management of these antibodies is critical in desensitization protocols, where they are targeted for removal through plasmapheresis or immunoadsorption to allow for successful cross-match incompatible procedures (Journal of Clinical Apheresis, 2020). Additionally, they play a role in ABO-hemolytic disease of the newborn, where maternal IgG Anti-B crosses the placenta to attack fetal red cells (Mayo Clinic, 2023). Therapeutic interventions often focus on reducing antibody titers to safe levels to prevent these life-threatening immune responses.

Other names

Anti-B isoagglutininsAnti-B agglutininsB-antibodyBlood group B antibody

Therapeutic strategies involve the physical removal of antibodies via plasmapheresis or immunoadsorption, neutralization using synthetic B-antigen analogs, or suppression of antibody-producing B-cells using monoclonal antibodies like rituximab.